Wang Songlin, Rienstra Chad M, Chen Kang
National Magnetic Resonance Facility at Madison (NMRFAM), University of Wisconsin-Madison, Madison, WI-53706, United States.
Department of Chemistry, University of Wisconsin-Madison, Madison, WI-53706, United States.
ChemMedChem. 2024 Dec 2;19(23):e202400340. doi: 10.1002/cmdc.202400340. Epub 2024 Sep 30.
During therapeutic protein development, two-dimensional (2D) heteronuclear NMR spectra can be a powerful analytical method for measuring protein higher order structure (HOS) in solution since the spectra exhibit much higher resolution than homonuclear H spectra. However, 2D NMR capabilities for characterizing protein HOS in crystalline states remain to be assessed, given the low C natural abundance and intrinsically broader lines in solid-state NMR (SSNMR). Herein, high-resolution heteronuclear correlation (HETCOR) SSNMR was utilized to directly measure intact crystal drug products of insulin human, insulin analogs of insulin lispro and insulin aspart. The fingerprint regions in 2D H-C HETCOR spectra were identified, which distinguished the insulin crystals in their primary structure, HOS heterogeneity and dynamics, as well as the manufacturing processes. The HOS heterogeneity in insulin analogs is consistent with their therapeutic effect of rapid action; while insulin human crystals showed more structural homogeneity, consistent with their slower pharmacokinetics (PK) peak time than insulin analogs. Therefore, heteronuclear NMR could be broadly applicable to study protein drug dosage forms from liquid to solid, yielding improved molecular level structure data for assessing drug HOS in biosimilar drug development.
在治疗性蛋白质研发过程中,二维(2D)异核核磁共振光谱可作为一种强大的分析方法,用于测定溶液中蛋白质的高级结构(HOS),因为该光谱比同核H光谱具有更高的分辨率。然而,鉴于碳的天然丰度较低以及固态核磁共振(SSNMR)中固有线宽本就较宽,用于表征晶体状态下蛋白质HOS的二维核磁共振能力仍有待评估。在此,利用高分辨率异核相关(HETCOR)固态核磁共振直接测量人胰岛素、赖脯胰岛素和门冬胰岛素等胰岛素类似物的完整晶体药物产品。确定了二维H-C HETCOR光谱中的指纹区域,这些区域在一级结构、HOS异质性和动力学以及制造工艺方面区分了胰岛素晶体。胰岛素类似物中的HOS异质性与其快速起效的治疗效果一致;而人胰岛素晶体显示出更高的结构同质性,与其比胰岛素类似物更慢的药代动力学(PK)峰值时间一致。因此,异核核磁共振可广泛应用于研究从液体到固体的蛋白质药物剂型,为生物类似药研发中评估药物HOS提供改进的分子水平结构数据。